IP Library › Granted Patent US 12,649,769
Granted Patent B2
US 12,649,769 · App. 17/642,855 · Granted Jun 9, 2026

Recombinant human neuregulin derivatives and use thereof

Inventor: Mingdong Zhou (Shanghai, CN)
Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
C07K14/4756A61P9/00C07K14/55C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,649,769
App. No.
17/642,855
Granted
Jun 9, 2026
Kind
B2
Abstract

Disclosed is a use of recombinant human neuregulin derivatives in preparing a medicine for preventing, treating, or reducing the progression of cardiovascular diseases in mammals. In particular, the present invention relates to a novel recombinant human NRG-FC protein and a use thereof in the treatment of cardiovascular diseases. The protein has a prolonged half-life and enhanced biological activity.

Claims (2)

1 . A Neuregulin (NRG) fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3.

2 . A pharmaceutical formulation, comprising the NRG fusion polypeptide of claim 1 and a pharmaceutically acceptable carrier, excipient or diluent.

Priority Claims (2)
CN 201910873003.9 · Sep 16, 2019 · national
CN 202010955006.X · Sep 11, 2020 · national
Continuity (1)
Related Publication 20230057622A1 · Feb 23, 2023
References Cited (28)
US 7271149B2 · Glaesner et al. · 2007 [cited by applicant]
US 10294287B2 · Greve · 2019 [cited by applicant]
US 10441633B2 · Mingdong · 2019 [cited by applicant]
US 10702585B2 · Mingdong · 2020 [cited by applicant]
US 11235031B2 · Caggiano et al. · 2022 [cited by applicant]
US 11253573B2 · Mingdong · 2022 [cited by applicant]
US 20160165860A1 · Ait-Ali et al. · 2016 [cited by applicant]
US 20190202881A1 · Greve · 2019 [cited by applicant]
CN 1276381A · 2000 [cited by applicant]
CN 104623633A · 2015 [cited by applicant]
CN 108623672A · 2018 [cited by applicant]
EP 3090756A1 · 2016 [cited by applicant]
JP 2017502969 · 2017 [cited by applicant]
KR 20080085082 · 2008 [cited by applicant]
KR 20140076570 · 2014 [cited by applicant]
KR 20160105443 · 2016 [cited by applicant]
KR 20170091096 · 2017 [cited by applicant]
KR 20180100237 · 2018 [cited by applicant]
WO WO2013053076A1 · 2013 [cited by applicant]
WO WO2016045493A1 · 2016 [cited by applicant]
WO WO2016069574A1 · 2016 [cited by applicant]
WO WO2018167320A1 · 2018 [cited by applicant]
WO WO2019143272A1 · 2019 [cited by applicant]
WO WO2019200033A1 · 2019 [cited by applicant]
International Search Report mailed Dec. 10, 2020 for International Application No. PCT/CN2020/114955 (26 pages). [cited by applicant]
Niranjana et al.,2016, “Fc IgG1 heavy chain constant region, partial [ [cited by applicant]
Wikipedia, “Signal Peptide,” As accessed on Aug. 27, 2025 (3 pages). Available online at: https://en.wikipedia.org/w/index.php?title=Signal_peptide&oldid=881137750. [cited by applicant]
Zhang et al., 2018, “NRG1-Fc improves metabolic health via dual hepatic and central action,” JCI Insight 3(5):1-12. [cited by applicant]